Aurora Cannabis Inc. (TSE:ACB - Free Report) - Equities research analysts at Roth Capital dropped their Q4 2025 earnings per share estimates for shares of Aurora Cannabis in a research note issued on Thursday, February 6th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings of $0.39 per share for the quarter, down from their previous forecast of $0.56. The consensus estimate for Aurora Cannabis' current full-year earnings is ($0.22) per share. Roth Capital also issued estimates for Aurora Cannabis' FY2026 earnings at $1.26 EPS.
A number of other equities research analysts have also issued reports on the stock. ATB Capital cut their target price on shares of Aurora Cannabis from C$11.00 to C$8.50 in a research note on Tuesday, December 17th. Atb Cap Markets raised Aurora Cannabis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Finally, TD Securities upgraded Aurora Cannabis to a "strong-buy" rating in a report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of C$7.11.
View Our Latest Report on Aurora Cannabis
Aurora Cannabis Stock Up 3.8 %
ACB traded up C$0.34 during trading on Monday, hitting C$9.40. The company had a trading volume of 901,151 shares, compared to its average volume of 671,641. The company has a market cap of C$514.26 million, a PE ratio of -11.61 and a beta of 2.71. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48. Aurora Cannabis has a 1-year low of C$3.84 and a 1-year high of C$12.85. The business has a 50-day moving average of C$6.30 and a 200-day moving average of C$7.20.
Aurora Cannabis Company Profile
(
Get Free Report)
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
See Also
Before you consider Aurora Cannabis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurora Cannabis wasn't on the list.
While Aurora Cannabis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
